• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

November 9, 2016
CenterWatch Staff

CiToxLAB, a preclinical CROs, has announced the acquisition of AccelLAB, a Canadian CRO specialized in the preclinical assessment of new medical devices. Through this acquisition, CiToxLAB Group reinforces its position in the non-clinical CRO arena and enlarges its services portfolio to medical devices, a fast growing area which offers large synergies with drug development, the CiToxLAB’s core business.

AccelLAB was founded in 2004 by Dr. Guy Leclerc, an Interventional Cardiologist who headed the department of Cardiology and Cardiac Surgery of the Centre Hospitalier de l’Université de Montreal (CHUM). As an interventional cardiologist practitioner, Guy Leclerc has been a pioneer in applying what we call today translational research in the field of medical devices, helping client companies in the development of new cardiac stents, valves, pacemakers, etc. The services were more recently enlarged to other areas such as orthopedic, ENT (Ear, Nose and Throat) and dermatology specialties.

AccelLAB has a staff of around 100 people and the facilities include operating rooms, in particular for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.

Dr. Jean-François Le Bigot, chairman and CEO of CiToxLAB Group, said, “We identified AccelLAB as a strategic target to make our group a more global services player in the Life Sciences Services arena. Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers in particular in the cardiovascular, orthopedic fields and more generally in the regenerative medicine. We have been convinced by the high scientific approaches of AccelLAB, the depth of itsmethods and technologies combined with strict regulatory compliance but also, by the personality of the founder Guy Leclerc who is so committed himself to the progress in translational research with a strong entrepreneurship spirit.”

Following this acquisition, Dr. Guy Leclerc remains the managing director of AccelLAB. CiToxLAB continues its growth strategy and becomes a group with more than 1.000 staff in four countries (France, Canada, Hungary and Denmark) and revenues upper to €100 million realized for more than a third in North America.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing